Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination
Summary
The purpose of the study is to determine whether combination of brinzolamide and brimonidine is safe and effective in patients with open-angle glaucoma or ocular hypertension.
Study Design
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Conditions
Open-Angle Glaucoma
Intervention
brinzolamide/brimonidine, brinzolamide, brimonidine, brinzolamide + brimonidine
Location
Contact Alcon Call Center For Trial Locations
Fort Worth
Texas
United States
76134
Status
Terminated
Source
Alcon Research
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00961649
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:19:56-0400
Clinical Trials
To compare the efficacy of a fixed Brinzolamide/Brimonidine combination with Brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium: yttrium-aluminum-garnet (...
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimat...
This study aims to evaluate the effect of fixed brinzolamide-brimonidine combination on intaocular pressure after uncomplicated phacoemulsification surgery. Patients scheduled for phacoem...
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% ...
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide...
PubMed Articles
Brinzolamide-induced Follicular Conjunctivitis.
We report a case of a patient who developed a severe case of follicular conjunctivitis from brinzolamide after 1.5 years of consistent use. This patient was re-challenged again after resolution of the...
When applied topically, oxymetazoline and brimonidine reduce the persistent facial erythema of rosacea; this effect is mediated by cutaneous vasoconstriction induced by postsynaptic activation of α-a...
Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
To treat glaucoma, conventional eye drops are often prescribed. However, the eye drops have limited effectiveness as a result of low drug bioavailability due to their rapid clearance from the preocula...
Metal-organic Frameworks, NH-MIL-88(Fe), as Carriers for Ophthalmic Delivery of Brimonidine.
We have proposed a metal-organic framework (MOF), NH-MIL-88(Fe), as a novel carrier for topical drug delivery to the eye. The NH-MIL-88(Fe) particles were prepared via a solvothermal synthesis method ...
To evaluate whether brimonidine can prevent cytotoxicity in human retinal pigment epithelial (RPE) and Müller (MIO) cells after exposure to amyloid-beta 1-42 (Aβ42).
Medical and Biotech [MESH] Definitions
Brimonidine Tartrate
A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
Brimonidine Tartrate, Timolol Maleate Drug Combination
A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.
Glaucoma, Open-angle
Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.
Hydrophthalmos
Congenital open-angle glaucoma that results from dysgenesis of the angle structures accompanied by increased intraocular pressure and enlargement of the eye. Treatment is both medical and surgical.
Travoprost
A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
